Fluphenazine enanthate结构式 
             
            
            
         | 
        常用名 | Fluphenazine enanthate | 英文名 | Fluphenazine enanthate | 
|---|---|---|---|---|
| CAS号 | 2746-81-8 | 分子量 | 549.69100 | |
| 密度 | 1.181g/cm3 | 沸点 | 629.4ºC at 760mmHg | |
| 分子式 | C29H38F3N3O2S | 熔点 | N/A | |
| MSDS | N/A | 闪点 | 334.4ºC | 
            Fluphenazine enanthate用途Fluphenazine enanthate 是第一种长效抗精神病药物,用于治疗精神分裂症。  | 
    
| 中文名 | 氟奋乃静庚酸酯 | 
|---|---|
| 英文名 | 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl heptanoate | 
| 英文别名 | 更多 | 
| 描述 | Fluphenazine enanthate 是第一种长效抗精神病药物,用于治疗精神分裂症。 | 
|---|---|
| 相关类别 | |
| 体内研究 | 氟奋乃静对映体(2,4,8mg/kg;IM)对回避行为的抑制作用分别持续16、23和28天[1]。氟奋乃静(8mg/kg)的饮酒行为在给药后24小时内几乎完全被抑制[1]。氟奋乃嗪(8 mg/kg)在大鼠体内产生短暂的体重损失[1]。动物模型:Wistar品系雄性成年大鼠54只[1]剂量:2、4、8mg/kg给药:中指数(IM)结果:3种剂量的氟哌嗪分别在16、23、28d时对回避行为有明显抑制作用。 | 
| 参考文献 | 
| 密度 | 1.181g/cm3 | 
|---|---|
| 沸点 | 629.4ºC at 760mmHg | 
| 分子式 | C29H38F3N3O2S | 
| 分子量 | 549.69100 | 
| 闪点 | 334.4ºC | 
| 精确质量 | 549.26400 | 
| PSA | 61.32000 | 
| LogP | 6.77020 | 
| 蒸汽压 | 9.41E-16mmHg at 25°C | 
| 折射率 | 1.544 | 
| 危险品运输编码 | UN 3249 | 
|---|---|
| 包装等级 | III | 
| 危险类别 | 6.1(b) | 
| 
                                    
                                    Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
                                    
                                    
                                     Int. Clin. Psychopharmacol. 28(5) , 261-6, (2013) Long-term follow-up data of patients with schizophrenia on depot antipsychotics have been few and the longest follow-up period has been up to 7 years. We carried out a systematic chart review to exami...  | 
                                |
| 
                                    
                                    Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
                                    
                                    
                                     Schizophr. Res. 119(1-3) , 153-9, (2010) This study aimed to characterize the inpatient utilization of depot antipsychotics.The characteristics of adults with schizophrenia or schizoaffective disorder, hospitalized for at least 28 days, and ...  | 
                                |
| 
                                    
                                    Multiple congenital abnormalities in a newborn boy associated with maternal use of fluphenazine enanthate and other drugs during pregnancy.
                                    
                                    
                                     Acta Paediatr. Scand. 71(2) , 335-8, (1982) A boy was born with a short sloping forehead, wide metopic suture, persistent metopic fontanelle, telecanthus, ocular hypertelorism, nystagmoid eye movements, bilateral cleft lip and palate, imperfora...  | 
                                
| Fluphenazine enantate | 
| 2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethyl heptanoate | 
| Fluphenazinenanthat | 
| Fluphenanzin-aenanthat | 
| 2-[4-[3-[2-(Trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl heptanoate | 
| Fluphenazin-aenanthsaeureester | 
| 4-<3-<2-Trifluormethyl-phenothiazinyl-(10)>-propyl>-1-(2-hydroxy-ethyl)-piperazin-heptanoat | 
| 1-heptanoyloxy-2-{4-[3-(2-trifluoromethyl-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethane | 
| Moditen-retard | 
| Prolixin Enanthate | 
| fluphenazine enanthate | 
| fluphenazine O-enantate | 
| Eutimox | 
| EINECS 220-385-0 |